Newsletter Subject

How to Earn a 37% Gain in 7 Hours

From

energyandcapital.com

Email Address

newsletter@energyandcapital.com

Sent On

Fri, Mar 15, 2024 03:01 PM

Email Preheader Text

Three things have happened that you absolutely need to know about... At one point, this stock was up

Three things have happened that you absolutely need to know about... [Energy and Capital Header] Practical Investment Analysis for the New Energy Economy How to Earn a 37% Gain in 7 Hours Jeff Siegel | Mar 15, 2024 Last week, I shared this chart with you … [mnmd2] At one point, this stock was up 86.8% in just over an hour. This is what happened to MindMed (NASDAQ: MNMD) after it was announced that the company had received breakthrough designation status from the FDA for its treatment for generalized anxiety disorder. If you’re unfamiliar, the FDA grants breakthrough status for drugs that treat life-threatening conditions, and clinical evidence shows that those drugs demonstrate substantial improvement over currently available treatments. Now what made this particularly interesting was that MindMed’s new medication is an EN-23 medication. 9 Billionaires Shifting Funds Here (Plus Warren Buffett) The smartest investors in the world are making a BIG move right now. David Tepper, Steve Cohen, Bill Gross, Paul Tudor Jones, Jeremy Grantham, George Soros, Carl Icahn, Jim Simons, and Larry Fink... They're jumping into oil and gas stocks with both feet. Meanwhile, 99% of investors can’t see what’s coming. According to Keith Kohl, our oil and gas analyst, three powerful economic triggers are converging on the oil markets right now... A "perfect storm" unlike anything we’ve seen in 50 years. The last time this happened, a small group of oil companies made 20x returns in a few years. Some gains were as high as 3,000%! That’s exactly the type of oil company Keith is recommending today.  He’s calling it "the No. 1 oil stock of the decade." [Get the name and ticker here before oil prices surge higher.]( If you’re unfamiliar, EN-23 is a valuable class of molecules that drastically improves brain function.  It’s actually one of the biggest breakthroughs medical science has seen in 50 years, because not only can it treat mental health conditions such as depression, anxiety, PTSD and addiction, it also has the ability to help you lose weight, treat chronic pain and even extend your lifespan by up to 20 years. Now over the past few weeks, three things have happened that you absolutely need to know about. First, the FDA granted breakthrough status for MindMed, which sent the stock soaring more than 58% in just one hour. Second, an analyst at J.P. Morgan let it slip that the behemoth investment bank (with assets in excess of $2.5 trillion) is now in dialogue with a number of companies developing new EN-23 treatments for mental health conditions. And third, the FDA announced another breakthrough therapy designation for another EN-23 company called Cybin (NYSE: CYBN). Here’s what happened right after that announcement … [cybn] Less than a week prior to this announcement, I told you the following … … at the moment, there are two EN-23 companies in particular that are next in line for breakthrough status designation from the FDA. And when that happens, expect to see the same result we saw last week with MindMed. Cybin was one of those two stocks. [URGENT: This Parcel of Land Could Gift You Half a Million Dollars]( [JMT Buried Under the Land Image](In a remote corner of North America, a team of geologists and explorers just found something truly amazing. Mining experts call it the last GREAT gold discovery on Earth. And if you invest in the tiny firm that owns this land — before Big Tech and Wall Street investors catch wind of it... You could turn $10,000 into over $500,000! [Get the lowdown on this urgent gold opportunity right now.]( That’s two EN-23 stocks getting FDA breakthrough therapy designations within two weeks. The third, dear reader, is coming up next. And I imagine you’d like to know the name of this stock before that happens. After all, the first two I told you about delivered a 58% gain in one hour and a 37.3% gain in just under 7 hours. There’s no doubt in my mind that this next EN-23 stock will be the next to get breakthrough therapy designation, and I want to make sure you own shares of this thing before that happens. That’s why I put together [this short investment note]( which includes all the information you need to know about this stock so you can grab shares before the FDA grants it breakthrough therapy designation. I also have a more in-depth presentation that also includes information on two more EN-23 stocks that I believe are in line for massive gains this year. [You can download that for free, here](. Given how fast the FDA is granting breakthrough therapy designations for these EN-23 companies, I highly recommend you buy shares of the company I believe will be the next to get this designation. Because mark my words: it’s going to happen fast! To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel [[follow basic]Check us out on YouTube!]( [[follow basic]@JeffSiegel on Twitter]( Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor's [page](. [Fb]( [Li]( [Tw]( This email was sent to {EMAIL}. You can manage your subscription and get our privacy policy [here](. Energy and Capital, Copyright © 3 East Read Street, Baltimore, MD 21202. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info [here]( including our privacy policy and information on how to manage your subscription. If you are interested in our other publications, please call our customer service team at [1-877-303-4529](tel:/18773034529).

Marketing emails from energyandcapital.com

View More
Sent On

26/05/2024

Sent On

25/05/2024

Sent On

25/05/2024

Sent On

24/05/2024

Sent On

24/05/2024

Sent On

23/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.